Imexpharm Corp
VN:IMP
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24 572.8953
97 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches VND.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Imexpharm Corp
Cost of Revenue
Imexpharm Corp
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Imexpharm Corp
VN:IMP
|
Cost of Revenue
-₫1.4T
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-12%
|
|
|
H
|
HaTay Pharmaceutical JSC
VN:DHT
|
Cost of Revenue
-₫1.8T
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-10%
|
|
|
C
|
Cuu Long Pharmaceutical JSC
VN:DCL
|
Cost of Revenue
-₫934B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
D
|
Domesco Medical Import Export Joint Stock Corp
VN:DMC
|
Cost of Revenue
-₫1.4T
|
CAGR 3-Years
-9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-3%
|
|
|
D
|
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
|
Cost of Revenue
-₫2.8T
|
CAGR 3-Years
-9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-5%
|
|
|
T
|
Traphaco JSC
VN:TRA
|
Cost of Revenue
-₫1.1T
|
CAGR 3-Years
14%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-2%
|
|
Imexpharm Corp
Glance View
Imexpharm Corp. engages in the manufacture, import, export and trade of pharmaceuticals, medicinal chemicals and botanical. The company is headquartered in Cao Lanh, Dong Thap and currently employs 1,356 full-time employees. The company went IPO on 2006-12-04. The firm manufactures, imports, exports and trades pharmaceutical products, antiseptics, traditional medicine, medical equipment and supplies, cosmetics, supplemental food and drinks. The company is also involved in the provision of packaging services and warehousing services for pharmaceutical storage purposes. In addition, the Company is involved in medicinal herb cultivation.
See Also
What is Imexpharm Corp's Cost of Revenue?
Cost of Revenue
-1.4T
VND
Based on the financial report for Sep 30, 2024, Imexpharm Corp's Cost of Revenue amounts to -1.4T VND.
What is Imexpharm Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-12%
Over the last year, the Cost of Revenue growth was -25%. The average annual Cost of Revenue growth rates for Imexpharm Corp have been -19% over the past three years , -12% over the past five years , and -12% over the past ten years .
You don't have any saved screeners yet
